fax: +39-0250320410
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Viral Hepatitis
You have full text access to this OnlineOpen article
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4†
Article first published online: 3 JAN 2012
DOI: 10.1002/hep.24683
Copyright © 2012 American Association for the Study of Liver Diseases
Additional Information
How to Cite
De Nicola, S., Aghemo, A., Grazia Rumi, M., Galmozzi, E., Valenti, L., Soffredini, R., De Francesco, R., Prati, G. M., D'Ambrosio, R., Cheroni, C., Donato, M. F. and Colombo, M. (2012), Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology, 55: 336–342. doi: 10.1002/hep.24683
- †
Potential conflicts of interest: Massimo Colombo, MD, Grant and research support: Merck, Roche, BMS, Gilead Science; Advisory committees: Merck, Roche, Novartis, Bayer, BMS, Gilead Science, Tibotec, Vertex, Achillion; Speaking and teaching: Tibotec, Roche, Novartis, Bayer, BMS, Gilead Science, Vertex. Maria Grazia Rumi, MD, Speaking and Teaching: Roche; Advisory committees: Jannsen; Travel support: Roche. Alessio Aghemo, MD, Advisory committees: Roche; Travel support: BMS, Glaxo Smith-Kline, Bayer. The other authors have no financial disclosures to declare.
- ‡
fax: +39-0250320410
Publication History
- Issue published online: 27 JAN 2012
- Article first published online: 3 JAN 2012
- Accepted manuscript online: 19 SEP 2011 09:08AM EST
- Manuscript Accepted: 3 SEP 2011
- Manuscript Received: 18 JUN 2011
Abstract
Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection. Whether this holds true for HCV-4 patients too is unknown. The aim was to investigate the predictive power of the rs12979860 IL28B SNP for a response to Peg-IFN and Rbv in HCV-4 patients. All HCV-4 patients consecutively treated between September 2004 and June 2010 with PegIFN and Rbv at two liver centers at the Maggiore Hospital Milan (Italy) underwent TaqMan SNP Genotyping assays for testing rs12979860 genotype. Of 112 treated patients (98 males, 75 of Egyptian descent, 26 with cirrhosis) 103 were included in the final analysis; five discontinued treatment for nonvirologic reasons and four did not consent to genetic testing. Twenty-four (23%) were genotype CC, 65 (63%) CT, and 14 (14%) TT. Overall, 50 (49%) achieved an SVR: 21 (88%) CC patients versus 29 (37%) CT/TT (P < 0.0001). CC patients more often had a rapid virologic response (RVR) than CT/TT patients (12, 50% versus 23, 29%; P = 0.08), while also showing lower relapse rates (0% [0/21] versus 36% [16/45] P = 0.0013). In non-RVR patients, SVR rates were higher in CC than CT/TT patients (9 [75%] versus 13 [23%] P = 0.001). By logistic regression, the IL28B rs12979860 CC genotype was an independent predictor of SVR with an odds ratio of 8.0 (95% confidence interval 2.00-32.01; P = 0.003). Conclusion: The IL28B rs12979860 SNP may have an added value in the treatment algorithm of HCV-4 patients because it is the strongest predictor of an SVR to PegIFN/Rbv therapy. (HEPATOLOGY 2012)